On Jul. 31, 2020, Quidel announced a preliminary contract with the NIH to support the expansion of its manufacturing capacity in San Diego for its diagnostic assays that test for SARS-CoV-2 Antigen using its Sofiaﾮ Fluorescence Immunoassay platform.